Skip to main content
micro-community-banner
 
  • Saved

Commented on 's Post

Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma - PubMed

B-cell non-Hodgkin's lymphoma (B-NHL) encompasses multiple clinically and phenotypically distinct subtypes of malignancy with unique molecular etiologies. Common subtypes of B-NHL such as diffuse large B-cell lymphoma (DLBCL) have been ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33792219/

Show More Comments

  • 2 weeks 2 days
    What are the specific strengths and weaknesses of this study? What future research should be done on the topic?
  • 2 weeks 3 days
    Very interesting study defining mutations common to b-nhl as well as more subtype specific mutational patterns
  • Saved

Commented on 's Post


TITLE: Clinical application of liquid biopsy in non-Hodgkin lymphoma
SUMMARY: In the case of DLBCL or any other (less) common NHL subtype, tissue diagnosis is the gold standard. ..... see more

Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma - PubMed

Non-Hodgkin lymphoma (NHL) is a common type of hematological malignant tumor, composed of multiple subtypes that originate from B lymphocytes, T lymphocytes, and natural killer cells. A diagnosis of NHL ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33816315/

Show More Comments

  • 2 weeks 3 days
    How far off is the development of prognostic models based on cfDNA/ctDNA for NHL? In your opinion, what research still needs to be done?
  • 2 weeks 4 days
    Only used in context of 10 color flow for CLL and in research setting in MCL. Few commercial platforms. Would speculate that this in conjunction with pet will improve Show More
  • Saved

Commented on 's Post

WVU Cancer Institute Cellular Therapy Program doubles CAR-T offerings with two new treatments | WVU Medicine

MORGANTOWN, W.Va. - The WVU Cancer Institute Osborn Hematopoietic Malignancy and Cellular Therapy Program is offering two new forms of chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of ..... see more

Source : https://wvumedicine.org/news/article/wvu-cancer-institute-cellular-therapy-program-doubles-car-t-offerings-with-two-new-treatments_0/

Show More Comments

  • 2 weeks 3 days
    This development is notable because it provides increased access to rural populations in West Virginia. Could this be a developing trend to combat health disparities?
  • 2 weeks 4 days
    Probably the case for many centers around the country ...
  • Saved

Commented on 's Post

Impact of Hypoalbuminemia on the Prognosis of Relapsed/Refractory B‐Cell Lymphoma Treated with Axicabtagene Ciloleucel

Mohamed A. Kharfan‐Dabaja Corresponding Author Division of Hematology‐Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA Corresponding Author: Mohamed A. see more

Source : https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13609

Show More Comments

  • 3 weeks 4 days
    Most surprising finding might be the two patients without a serum albumin prior to car T. That aside, there is a difficult to explain disconnect between ORR and PFS/OS Show More
  • Saved

Commented on 's Post

The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling

Rationale: Primary central nervous system diffuse large B-cell lymphoma (PCNSL) is a rare and aggressive entity that resides in an immune-privileged site. The tumor microenvironment (TME) and the disruption of ..... see more

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914352/

Show More Comments

  • 3 weeks 4 days
    Wow. Very complex article dividing pcnsl into subgroups based on a multifaceted immune signature that may have important prognostic and therapeutic implications if confirmed
  • Saved

Commented on 's Post

Current treatment options for aggressive non-Hodgkin lymphoma in elderly and frail patients: practical considerations for the hematologist - Katrin Schmittlutz, Reinhard Marks, 2021

Abstract Treatment decisions for aggressive non-Hodgkin lymphoma in elderly and frail patients still remain challenging. The heterogeneity of elderly patients consists of various physical and psychological states, coexisting comorbidities as ..... see more

Source : https://journals.sagepub.com/doi/full/10.1177/2040620721996484

Show More Comments

  • 3 weeks 5 days
    This is a nice review on elderly dlbcl. It seems likely that with newer less toxic therapies and better categorization of elderly patients into functional categories that we will Show More
  • Saved

Commented on 's Post

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma - PubMed

The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33202794/

Show More Comments

  • 3 weeks 5 days
    It’s exciting how many supposedly non cross resistant targets we are identifying for this disease including cd19 and cd79 in addition to cd20. These therapies with various mechanisms of Show More
  • Saved

Commented on 's Post

Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs - PubMed

1 Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Science, Tehran, Iran. 2 Department of Medical Genetics, Iran University of Medical Sciences (IUMS), Tehran, Iran; Medical Genetics ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33789222/

Show More Comments

  • 3 weeks 5 days
    What will come to the clinic faster ....effective NK car therapy with reduced toxicities or car T cells with reduced toxicity with off switches as this article describes ?
  • Saved

Commented on 's Post

Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade - PubMed

1 Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Université de Rennes, Établissement Français du Sang de Bretagne, INSERM, Rennes, France. 2 Laboratoire d'Hématologie, Centre Hospitalier Universitaire, Rennes, France. 3 INSERM UMR ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33787861/

Show More Comments

  • 3 weeks 5 days
    Interesting kind of research. Will be interesting to see if the findings from this study can be translated to improved T cell mediated anti lymphoma therapeutics in the future Show More
  • Saved

Commented on 's Post

Increased Malat1 Expression Predicts Poor Prognosis in Primary Gastrointestinal Diffuse Large B-cell Lymphoma

Increased Malat1 Expression Predicts Poor Prognosis in Primary Gastrointestinal Diffuse Large B-cell Lymphoma see more

Source : https://europepmc.org/article/ppr/ppr296017

Show More Comments

  • 3 weeks 5 days
    Malat1 hasn’t received much attention in lymphoma and this opens a potentially important line of future research both from a prognostic and predictive standpoint
  • Saved

Commented on 's Post

End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA - PubMed

GOYA was a randomized phase 3 study comparing obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) vs standard-of-care rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33651099/

Show More Comments

  • 3 weeks 5 days
    While one would assume a link between end of treatment pet cR vs other response category would predict pfs in an aggressive and curable disease , it’s always nice to Show More
  • Saved

Commented on 's Post

Show More Comments

  • 3 weeks 6 days
    This case highlights the importance of a comprehensive flow histopath genetic and molecular workup on blood cancers as variants of even rare subtypes do exist and this becomes critical info Show More
  • Saved

Commented on 's Post

Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas - PubMed

The introduction of novel targeted agents and immunotherapeutic modalities into the treatment of B-cell lymphomas has drastically shifted the treatment landscape. In diffuse large B-cell lymphoma, recent approvals of CAR ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33770460/

Show More Comments

  • 3 weeks 6 days
    We are likely at the tip of the iceberg in regards to immunotherapy as additional car T, nk cell therapy, and bispecific immunotherapy are likely to see expansion and integration Show More
  • Saved

Commented on 's Post

The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy - PubMed

CD19-targeted chimeric antigen receptor (CAR) T cells have shown excellent activity against relapsed and refractory (R/R) diffuse large B cell lymphoma (DLBCL). CAR T cell therapy is associated with early ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33781518/

Show More Comments

  • 3 weeks 6 days
    Given that carTs often cancel higher risk subsets of disease, such as double hit genetics, it’s surprising that a simple clinical risk score would be predictive of outcome ....
  • Saved

Commented on 's Post

Tafasitamab: First Approval - PubMed

Tafasitamab (tafasitamab-cxix; MONJUVI ® ) is an Fc-modified (i.e. two amino acid substitutions within the Fc region, resulting in increased Fcγ receptor affinity), humanized, anti-CD19 monoclonal antibody. Developed by MorphoSys ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/32946059/

Show More Comments

  • 3 weeks 6 days
    This anticd19 antibody is an exciting pairing with another immunotherapeutic, revlimid, and I would expect that this antibody will gain additional treatment partners and indications both in dlbcl and other Show More
  • Saved

Commented on 's Post

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma

ABSTRACT Patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) require further treatment options, especially in cases that cannot tolerate stem cell transplant or cytotoxic chemotherapy. CD19 has ..... see more

Source : https://doi.org/10.1080/14712598.2021.1884677

Show More Comments

  • 1 month
    Tafa and rev individually have low but respectable single agent activity in dlbcl that is enhanced significantly in combination and the dor is very exciting in a subset of patients Show More
  • Saved

Commented on 's Post

Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential - PubMed

Shallow-depth sequencing of cell-free DNA, a cheap and standardized approach to obtain molecular information on tumors non-invasively, is insufficiently explored for lymphoma diagnosis and disease follow-up. This study collected 318 ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33299235/

Show More Comments

  • 1 month
    This is exciting work. There are limitations to current diagnostic classification that may be overcome in the future by a greater reliance on molecular data Seems likely that Show More
  • Saved

Commented on 's Post

Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients - PubMed

Most patients with diffuse large B-cell lymphoma (DLBCL) are diagnosed at age 60 years or older. Challenges to effective therapy among older individuals include unfavorable biologic features of DLBCL, geriatric ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33230948/

Show More Comments

  • 1 month
    Outcomes in elderly dlbcl are worse than younger patients due to both both disease and patient characteristics. This review highlights present challenges but expresses hope for the future with Show More
  • Saved

Commented on 's Post

Epstein-Barr virus-positive diffuse large B-cell lymphoma with human immunodeficiency virus mimicking complicated frontal sinusitis: A case report - PubMed

Through this article, we suggest that EBV-positive DLBCL should be considered as possible diagnosis for patients with nonspecific space-occupying lesion of the paranasal sinuses. We also highlight an importance of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33728309/

Show More Comments

  • 1 month
    Ebv should not only be considered for dlbcl arising out of immunosuppression but also considered with head and neck predominant presentations of dlbcl In spite of ebv detection Show More
  • Saved

Commented on 's Post

Ki67 Proliferation Index in Germinal and Non-Germinal Subtypes of Diffuse Large B-Cell Lymphoma - PubMed

Introduction Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma. The 2016 World Health Organization (WHO) update on hematopoietic tumors suggested that all DLBCL cases should be subtyped into ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33728138/

Show More Comments

  • 1 month
    Ki67 has long been a weak prognostic factor in dlbcl. This is the first I’ve seen of subtype specific ki67 information and the first association with myc IHC positivity Show More